Diabetes Mellitus Clinical Trial
Official title:
An Explorative Study of a Novel Non-invasive Glucose Measuring Device in Out-patient Settings
Verified date | November 2023 |
Source | RSP Systems A/S |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This explorative clinical investigation has been launched to collect spectral Raman data paired with validated glucose reference values in persons with diabetes.
Status | Completed |
Enrollment | 173 |
Est. completion date | April 23, 2022 |
Est. primary completion date | April 23, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Male and female subjects minimum 18 years of age - Individuals diagnosed with any type of insulin-dependent diabetes mellitus = 1 year - Willing to perform up to 12 finger-pricks during each day of out-patient measurements - Signed informed consent - For women of childbearing potential: Willing and able to practice FDA approved birth control during the duration of the investigation - Subject has a 2.4 GHz wireless internet connection at home (standard in normal routers) to be used in the study Exclusion Criteria: - For female subjects: Pregnancy or breastfeeding - Skin phototype VI categorized by Fitzpatrick scale measured on thenar - Subjects not able to understand and read local language - Cognitive impairment, or in investigator's opinion, subject is not able to follow instructions provided and as specified in the protocol - Subject not able to hold hand/arm steady (including tremors and Parkinson's Disease) - Extensive skin changes, tattoos or diseases on right thenar (measurement site) - Reduced circulation in right hand evaluated by Allen's test - Known allergy to medical grade alcohol - Hemodialysis - Systemic or topical administration of glucocorticoids at the right hand for the past 7 days or during the study period expected - Any disorder, which in the investigator's opinion might jeopardize subject's safety or compliance with the protocol - Severe diabetes-related complications such as advanced autonomic neuropathy, kidney disease, foot ulcers, legal blindness, or symptomatic cardiovascular disease as evidenced by a history of cardiovascular episode(s) - Dependency from the sponsor or the clinical investigator (e.g. co-workers of the sponsor, the study site, and/ or their families) - Subjects currently participating in another study - Subjects who have participated in the study IDT-1904-RO/RSP-21 or RSP-19. - Incapacity for consent |
Country | Name | City | State |
---|---|---|---|
Germany | Institut für Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm | Ulm |
Lead Sponsor | Collaborator |
---|---|
RSP Systems A/S |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Determination of number of calibration days | The number of calibration days needed for reaching a well-performing glucose predictive calibration model will be determined. The clinical performance of the reduced calibration model will be based on the data from the validation part by studying linear regression, Inter Subject Unified Performance value and Consensus Error Grid. | 2 years | |
Primary | Safety evaluation of the Investigational Medical Device by reporting of adverse events | Safety of the IMD will be evaluated in a descriptive manner by the paucity of adverse events reported during the clinical investigation | 2 years | |
Secondary | Device function | Device function will be evaluated in regard to durability and reliability. This is evaluated by reported device deficiencies during the study in the terms of subject diaries | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |